Expand OSTX Menu
OSTX MENU

OSTX Latest Press Releases

-- September 17, 2026 --

OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program Newsfile 7:14 AM
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program Newsfile 6:02 AM

-- September 15, 2026 --

OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing Newsfile 7:46 AM

-- September 8, 2026 --

OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial Newsfile 6:00 AM

-- September 2, 2026 --

OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance Newsfile 7:21 AM

-- August 17, 2026 --

OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates Newsfile 7:40 AM

-- August 13, 2026 --

OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma Newsfile 8:45 AM

-- July 8, 2026 --

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program Newsfile 9:02 AM

-- July 6, 2026 --

OS Therapies Third Quarter 2026 Corporate Outlook Newsfile 9:01 AM

-- July 2, 2026 --

OS Therapies Appoints Dr. Craig Eagle to Board of Directors Newsfile 7:33 AM

-- June 30, 2026 --

OS Therapies Provides U.S. Regulatory Update Newsfile 7:41 AM

-- June 26, 2026 --

OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma Newsfile 7:41 AM

-- June 8, 2026 --

OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma Newsfile 6:02 AM

-- June 2, 2026 --

OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma Newsfile 6:01 AM

-- May 29, 2026 --

OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World Newsfile 7:21 AM

-- May 26, 2026 --

OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences Newsfile 7:41 AM

-- May 18, 2026 --

OS Therapies Reports First Quarter 2026 Financials and Provides Business Update Newsfile 6:32 AM

-- May 15, 2026 --

OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 Newsfile 4:05 PM

-- May 14, 2026 --

OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor Newsfile 7:30 AM

-- April 30, 2026 --

OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma Newsfile 7:17 AM
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma Newsfile 6:00 AM

-- April 28, 2026 --

OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET Newsfile 2:03 PM

-- April 27, 2026 --

OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET Newsfile 4:01 PM
Market Data Delayed 15 Minutes